Day: August 12, 2021

• Feedzai received highest score possible in 12 criteria, including model building, rules-based risk scoring and alerting, data integration, and segmentation and behavioral profiles 

SAN MATEO, Calif. and LISBON, Portugal, Aug. 12, 2021 (GLOBE NEWSWIRE) — Feedzai, the world’s leading cloud-based financial risk management platform, announced that it has been recognized as a Strong Performer in The Forrester Wave™: Enterprise Fraud Management, Q3 2021 Report. The report ranked Feedzai among the top three companies in the strategy category, with scores of 5 out of 5 in eight of the strategy criteria. In addition, Feedzai earned scores of 5 out of 5 in four criteria in the current offering category.

The report evaluated the top enterprise fraud management (EFM) providers and narrowed the scope to those most significant. The evaluation shows how each provider measures up and helps risk management and fraud management professionals select the right solution for their needs.

Feedzai received highest marks possible for criteria that Feedzai believes indicate the strength of its current offering as well as the organization’s strong strategic vision. Feedzai Transaction Fraud achieved the highest scores possible (5 out of 5) in the model building, segmentation and behavioral profiles, data integration, and rules-based risk scoring and alerting. Within the strategy category, the company also received the highest scores possible in the data integration plans, data scientist workflow improvement plans, and investigation and analyst workflow plans. We believe these scores align with the components deemed important by Forrester for EFM customers. According to the report, customers should look for vendors that:

• Provide a flexible and customizable workflow for citizen data scientists to build a model.
  • Feedzai scored 5/5 in the model building criterion.

• Integrate the customer’s own and third-party data fast with quality checks and workflow.
  • Feedzai scored 5/5 in the data integration criterion.

• Automate maintenance of segmentation of customers and entities.
  • Feedzai scored 5/5 in the segmentation and behavioral profiles criterion.

According to the Forrester Wave Report, “Feedzai offers a strong data integration workflow… Capabilities for checking the quality of transaction data that the solution uses for decisioning are configurable and extensive. Rule authoring and versioning are ahead of the competition. The solution also provides a differentiating automatic user segmentation recommendation and creation capability.” The report also states, “Feedzai’s plans for data integration and unsupervised machine learning are ahead,” and “the solution is a nice fit for firms looking for explainable AI models provided on a model authoring workbench.”

“The cashless commerce transition continues to accelerate, but the digitization requirements have changed,” said Varun Kohli, CMO at Feedzai. “Feedzai solutions are engineered to address the high velocity of change in payment and nonpayment fraud. We believe Forrester’s EFM report puts the spotlight on the strength of components that make up the cornerstone of our products. It’s validating to see our products and strategy recognized by a respected third-party. We are continuing to invest in both product innovation and strategy, and we expect our upward trajectory to continue.” The executive added, “Feedzai’s 5/5 score in the segmentation and behavioral profiles criterion – which did not take into account Revelock’s acquisition announced after the report completion – is, in our opinion, a powerful indicator that we are ahead of everyone else in this and other domains.”

Feedzai continues to pave the way with the most advanced cloud platform to manage financial risk, while researching promising machine learning techniques to better protect customers and businesses all over the world. The company also continues protecting its growing technology portfolio with 10 new patents filed in the last 12 months on Responsible AI, Deep Learning, MLOps Automation, AI Observability, and more. The company invests around 26% of its revenue in R&D every year, while the average investment made by successful SaaS companies sits at 23%.

Feedzai’s capabilities are proven across the largest banks, fintechs, e-commerce merchants, and payment processors in the world while providing the only single platform with omnichannel capabilities to manage financial risk.

For a full copy of the Forrester report, go to: https://feedzai.com/resource/forrester-wave-enterprise-fraud-management-report/

About Feedzai
Feedzai is the market leader in safeguarding global commerce with today’s most advanced cloud-based risk management platform, powered by machine learning and artificial intelligence. Feedzai is securing the transition to a cashless world while enabling digital trust in every transaction and payment type. The world’s largest banks, processors, and retailers trust Feedzai to protect trillions of dollars and manage risk while improving the customer experience for everyday users, without compromising privacy. Feedzai is a Series D company and has raised $282M to date with a current valuation of well over $1B. Its technology protects 800 million people in 190 countries. For more information, visit feedzai.com.

Igor Carvalho
Head of Global Communications, Feedzai
igor.carvalho@feedzai.com

1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA

SHANGHAI, China and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the United States Food and Drug Administration (“FDA”) has recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the 1^st line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The FDA had earlier granted BTD for toripalimab monotherapy for patients with recurrent or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

BTD is intended to expedite the development and regulatory review of drugs where preliminary clinical evidence demonstrates substantial improvement over existing therapies for a severe or life-threating disease. Drugs with BTD will be granted closer FDA guidance – including that from senior FDA officials – and various forms of support to avail patients with new therapy as soon as possible.

Junshi Biosciences expects to complete the biologics license application (“BLA”) submission for toripalimab plus chemotherapy for 1st line NPC and for toripalimab monotherapy for 2nd or 3rd line NPC later this quarter.

“We are pleased to have received Breakthrough Therapy designation for our novel PD-1 blocking antibody, toripalimab, for nasopharyngeal carcinoma, which is an aggressive cancer with no immuno-oncology treatment options approved in the United States,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “We look forward to working closely with the FDA during the BLA review process and with our partner, Coherus, to bring toripalimab to NPC patients in the U.S., if approved.”

The Breakthrough Therapy designation is supported by data from the Phase 3 clinical trial “JUPITER-02” evaluating toripalimab in combination with chemotherapy for the first-line treatment of NPC. In this study, toripalimab in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression free survival (“PFS”) compared to chemotherapy alone (assessed by a blinded independent review committee (“BIRC”) per RECIST v1.1). JUPITER-02 also met secondary endpoints of PFS assessed by the investigator and objective response rate assessed by BIRC. There was also a longer duration of response, a higher disease control rate, and higher one- and two-year survival rates for the toripalimab arm. The safety profile of toripalimab is consistent with that observed in previously reported toripalimab clinical trials and the safety profile of this class of drugs. The result of JUPITER-02 was recently presented at the ASCO plenary session (#LBA2) and full results can be found in the August 2021 on-line edition of Nature Medicine.

About toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. Pivotal clinical trials are ongoing or completed evaluating the safety and efficacy of toripalimab for a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI^®). On December 17, 2018, toripalimab was granted a conditional approval from the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In December 2020, toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the supplemental NDA for toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced, recurrent or metastatic nasopharyngeal carcinoma was accepted by the NMPA. In the same month, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. In April, NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

In the United States, a rolling submission of the first toripalimab Biologics License Application (BLA) is underway for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the 1^st line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and also for toripalimab monotherapy in second or third line treatment of recurrent or metastatic NPC. There are currently no PD-1 blocking antibodies indicated for use in NPC in the United States. Additionally, FDA has granted Fast Track status for the development of toripalimab for the treatment of mucosal melanoma and orphan drug designation for NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021 Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare cancers and highly prevalent cancers.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) by US FDA in Feb 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.

Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch toripalimab, an anti-PD-1 antibody, as well as biosimilars of Lucentis®, Humira®, and Avastin®, if approved.

UDENYCA® is a trademark of Coherus BioSciences, Inc.
Avastin® and Lucentis® are registered trademarks of Genentech, Inc.
Humira® is a registered trademark of AbbVie Inc.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ ability to generate cash flow from its UDENYCA® business; Coherus’ and Junshi Biosciences’ ability to co-develop toripalimab, and Coherus’ ability to commercialize toripalimab, or any other drug candidates developed as part of its collaboration with Junshi Biosciences in the licensed territory; the potential for toripalimab to gain approval in the United States for nasopharyngeal carcinoma or any indication; Coherus’ and Junshi Biosciences’ plans to file additional toripalimab BLAs with the FDA over the next three years for other clinical indications; Coherus’ plans to invest the cash generated by its biosimilar commercial business to build a focused immuno-oncology franchise; Coherus’ ability to prepare for projected launches through 2023 of biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021, filed with the Securities and Exchange Commission on August 5, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Results for the quarter ended June 30, 2021 are not necessarily indicative of our operating results for any future periods.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Coherus Contact Information:

IR Contact:
McDavid Stilwell
Coherus BioSciences, Inc.
mstilwell@coherus.com
+1 (650) 395-0152

Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
+1 (949) 903-4750

NEXEN TIRE and official partner Manchester City Football Club kick off new Premier League 2021-22 season

• The cooperation with Manchester City, which begun in 2015, will be continued in the 2021/22 season.
• Increased engagement with fans and customers through a variety of online activities
• Shared growth achieved through strategic alliances during a worldwide epidemic

SEOUL, South Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) — NEXEN TIRE, a leading global tire manufacturer, is proud to continue its successful partnership with Manchester City Football Club for the new 2021/22 season of the Premier League.

Since 2015, NEXEN TIRE has been an official partner of the world-class football club Manchester City. Despite challenges brought about by the global pandemic, the two partners are now preparing to kick off their seventh consecutive season together.

As a result of the COVID-19 crisis, NEXEN TIRE has increased its engagement with global followers through online events and content distribution like the Purple Live, Digital fan engagement campaign, virtual fitness challenge Nexen Road to Man City, and Road Trip Challenge, the latter where Man City players were challenged to pronounce the names of road trip locations around the world and in Korea. With Manchester City entering the new 2021/22 season, the Company will continue to raise its interaction with fans using a variety of methods.

While NEXEN TIRE was able to raise global awareness through expanding its global market share, the Man City partnership also enabled the Company to offer OE tires to a variety of automakers across the world.

A long-term, trust-based connection with Manchester City has been a significant springboard for both firms,” said Travis Kang, Global CEO of Nexen Tire. “Manchester City will undoubtedly perform well in the Premier League this season.”

During the 2020/21 season, NEXEN TIRE and its business partners utilized its partnership with Man City to promote strategic sales like co-marketing events for consumers in Asia, the Middle East, Latin American and Africa. Going forward, the Company looks to expand further in preparation for post-Covid operations during the 2021/22 season.

About Nexen Tire

Nexen Tire, established in 1942, is a global tire manufacturer headquartered in South Korea. Nexen Tire, one of the world’s fastest growing tire manufacturers, currently interacts with approximately 150 countries around the world and owns four manufacturing plants – two in Korea (Yangsan and Changnyeong), one in Qingdao, China and another plant in Žatec, the Czech Republic. Nexen Tire produces tires for passenger cars, SUVs, and light trucks with advanced technology and excellence in design. Nexen Tire supplies OE tires to global car makers in various countries around the world. In 2014, the company achieved a grand slam of the world’s top 4 design awards for the first time amongst the various tire makers in the world. Nexen Tire has been a successful sports sponsor in a variety of events in Europe ranging football to ice hockey such as Manchester City F.C., Eintracht Frankfurt, and BK Mladá Boleslav.

For more information, please visit https://www.nexentire.com/international/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49cdf6cb-a558-4ff5-bdad-0a1960af0d79

CONTACT: Sylvia Chang, sylvia.chang@pivotp.co.kr